KLRC1 and neoplasm: HLA-E-Qa-1b complexes, presenting specific peptides processed by endoplasmic reticulum aminopeptidase 1-2 (ERAP1-2), engage the inhibitory natural killer cell group 2 member A (NKG2A)-CD94 heterodimer on a subset of CD8+ tumor-infiltrating lymphocytes (TILs), leading to suppression of TCR signaling and consequent impairment of cytotoxic effector function (33, 34).